MedElevator
Войти в исследования Journal of clinical anesthesia · 2026
Toward precision risk stratification of postoperative cognitive dysfunction: Preoperative inflammatory and neurodegenerative protein biomarkers in orthopedic surgery: A systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alwesabi Abdulrahman Khaled, Gao Boxiong, Ma Yuhu, Xie Jinxiang, Xie Jiayi, Liu Yatao
Аннотация
BACKGROUND: Postoperative Cognitive Dysfunction (POCD) is a common complication in older adults undergoing major surgery and is associated with prolonged recovery and long-term cognitive decline. Identification of reliable preoperative protein biomarkers may enable early risk stratification and personalized perioperative management.
METHODS: We conducted a systematic review of prospective cohort studies evaluating preoperative inflammatory and neurodegenerative protein biomarkers and subsequent POCD. PubMed, Embase, Web of Science, Cochrane CENTRAL, and Scopus were searched from inception to October 30, 2025. Eligible studies measured protein biomarkers in blood or cerebrospinal fluid (CSF) before surgery and reported structured postoperative cognitive outcomes. Risk of bias was assessed using the Newcastle-Ottawa Scale. Due to heterogeneity in biomarkers, assays, and POCD definitions, findings were synthesized narratively.
RESULTS: Six prospective cohort studies involving 705 patients undergoing major orthopedic surgery were included. Biomarkers evaluated comprised inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-8, CRP), neuronal and glial injury markers (S100B, NSE, GFAP, NFL), and Alzheimer-related CSF proteins (Aβ₁₋₄₂, Aβ₄₀, total tau, phosphorylated tau). Lower preoperative CSF Aβ₁₋₄₂ levels and reduced Aβ/tau ratios were the most consistent predictors of POCD. Single serum biomarkers, including S100B and inflammatory cytokines, demonstrated variable or limited predictive value. Composite inflammatory profiles showed potential for identifying patients at risk of long-term cognitive decline.
CONCLUSIONS: Preoperative CSF amyloid-related biomarkers demonstrated relatively stronger associations with POCD in the available studies; however, evidence remains limited and further validation is required, while multi-marker inflammatory signatures may enhance risk assessment. Standardized studies are required to support clinical implementation.
METHODS: We conducted a systematic review of prospective cohort studies evaluating preoperative inflammatory and neurodegenerative protein biomarkers and subsequent POCD. PubMed, Embase, Web of Science, Cochrane CENTRAL, and Scopus were searched from inception to October 30, 2025. Eligible studies measured protein biomarkers in blood or cerebrospinal fluid (CSF) before surgery and reported structured postoperative cognitive outcomes. Risk of bias was assessed using the Newcastle-Ottawa Scale. Due to heterogeneity in biomarkers, assays, and POCD definitions, findings were synthesized narratively.
RESULTS: Six prospective cohort studies involving 705 patients undergoing major orthopedic surgery were included. Biomarkers evaluated comprised inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-8, CRP), neuronal and glial injury markers (S100B, NSE, GFAP, NFL), and Alzheimer-related CSF proteins (Aβ₁₋₄₂, Aβ₄₀, total tau, phosphorylated tau). Lower preoperative CSF Aβ₁₋₄₂ levels and reduced Aβ/tau ratios were the most consistent predictors of POCD. Single serum biomarkers, including S100B and inflammatory cytokines, demonstrated variable or limited predictive value. Composite inflammatory profiles showed potential for identifying patients at risk of long-term cognitive decline.
CONCLUSIONS: Preoperative CSF amyloid-related biomarkers demonstrated relatively stronger associations with POCD in the available studies; however, evidence remains limited and further validation is required, while multi-marker inflammatory signatures may enhance risk assessment. Standardized studies are required to support clinical implementation.